<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2013-9-2-133-137</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-250</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ANALYSIS OF CLINICAL PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АНАЛИЗ КЛИНИЧЕСКОЙ ПРАКТИКИ</subject></subj-group></article-categories><title-group><article-title>MEDICAL SUPERVISION IN SPECIALIZED CENTER AND THE QUALITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASES (ACCORDING TO THE PROFIL REGISTER)</article-title><trans-title-group xml:lang="ru"><trans-title>НАБЛЮДЕНИЕ В СПЕЦИАЛИЗИРОВАННОМ МЕДИЦИНСКОМ ЦЕНТРЕ И КАЧЕСТВО ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ У ПАЦИЕНТОВ С СЕРДЕЧНО-СОСУДИСТЫМИ ЗАБОЛЕВАНИЯМИ (ПО ДАННЫМ РЕГИСТРА ПРОФИЛЬ)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martsevich</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марцевич Сергей Юрьевич — доктор медицинских наук, профессор, руководитель отдела профилактической фармакотерапии ГНИЦ ПМ, профессор кафедры доказательной медицины Первого МГМУ им. И.М. Сеченова</p></bio><email xlink:type="simple">martsevich@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гайсёнок</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gaysenok</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гайсёнок Олег Владимирович — врач-кардиолог отделения общей кардиологии ОБП УД Президента РФ</p></bio><email xlink:type="simple">martsevich@gnicpm.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трипкош</surname><given-names>С. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tripkosh</surname><given-names>S. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трипкош Светлана Григорьевна - аспирант отдела профилактической фармакотерапии</p></bio><email xlink:type="simple">martsevich@gnicpm.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загребельный</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagrebelnyy</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Загребельный Александр Васильевич — кандидат медицинских наук, старший научный сотрудник отдела профилактической фармакотерапии</p></bio><email xlink:type="simple">martsevich@gnicpm.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукина</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukina</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лукина Юлия Владимировна — кандидат медицинских наук, старший научный сотрудник отдела профилактической фармакотерапии</p></bio><email xlink:type="simple">martsevich@gnicpm.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины, Москва;&#13;
Первый Московский государственный медицинский университет им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine, Moscow;&#13;
I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины, Москва;&#13;
Объединённая больница с поликлиникой Управления Делами Президента Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine, Moscow;&#13;
Joint Hospital and Polyclinic, Department of Affairs of the President of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>09</month><year>2015</year></pub-date><volume>9</volume><issue>2</issue><fpage>133</fpage><lpage>137</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Martsevich S.Y., Gaysenok O.V., Tripkosh S.G., Zagrebelnyy A.V., Lukina Y.V., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Марцевич С.Ю., Гайсёнок О.В., Трипкош С.Г., Загребельный А.В., Лукина Ю.В.</copyright-holder><copyright-holder xml:lang="en">Martsevich S.Y., Gaysenok O.V., Tripkosh S.G., Zagrebelnyy A.V., Lukina Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/250">https://www.rpcardio.online/jour/article/view/250</self-uri><abstract><sec><title>Aim</title><p>Aim. To assess the quality of lipid-lowering therapy in high risk patients with cardiovascular diseases during medical supervision in specialized center.</p></sec><sec><title>Material and methods</title><p>Material and methods. The data of the PROFIL register are used. All patients having cardiovascular diseases, high cardiovascular risk, and seeking medical attention in specialized medical center were enrolled into this register. Patients (n=274) were split into groups: control group (n=82, patients who have applied for the first time for medical care), the main subgroup A (n=167; patients observed last 2 years), and the main subgroup B (n=25; patients observed more than 2 years).</p></sec><sec><title>Results</title><p>Results. The total cholesterol blood level was significantly lower in the main group compared to the control (p&lt;0.05). Statins were constantly taken by 34% of patients in the control group, 71.6% - in subgroup A, and 61% - in subgroup B (p&lt;0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. Medical supervision in specialized medical center leads to better blood lipid control and patient compliance to statin therapy.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Оценить качество коррекции нарушений липидного обмена у больных сердечно-сосудистыми заболеваниями с высоким риском осложнений при наблюдении в специализированном медицинском центре.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Использованы данные регистра ПРОФИЛЬ, в который включаются все больные, обращающиеся в специализированный медицинский центр по поводу сердечно-сосудистых заболеваний и имеющие высокий риск сердечно-сосудистых осложнений. В исследование включено 274 больных, которые были раз- делены на группы: контрольная группа (n=82; впервые обратившиеся пациенты) и основная подгруппа А (n=167; пациенты, наблюдавшиеся в последние 2 года) и основная подгруппа Б (n=25; пациенты, наблюдавшиеся более 2 лет).</p></sec><sec><title>Результаты</title><p>Результаты. Уровень общего холестерина был значимо ниже в основной группе по сравнению с контролем. Постоянно принимали статины 34% больных контроль- ной группы, 71,6% больных подгруппы А и 61% больных подгруппы Б (p&lt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Наблюдение в специализированном медицинском центре способствует улучшению коррекции нарушений липидного обмена у пациентов и повышает их приверженность терапии статинами.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гиполипидемическая терапия</kwd><kwd>статины</kwd><kwd>приверженность терапии</kwd><kwd>регистр</kwd></kwd-group><kwd-group xml:lang="en"><kwd>lipid-lowering therapy</kwd><kwd>statins</kwd><kwd>compliance to therapy</kwd><kwd>register</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–1158.</mixed-citation><mixed-citation xml:lang="en">Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–1158.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.</mixed-citation><mixed-citation xml:lang="en">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615–1622.</mixed-citation><mixed-citation xml:lang="en">Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615–1622.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818</mixed-citation><mixed-citation xml:lang="en">ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Susekov A., M. Zubarev, Deev AD etc. The main results of the Moscow study on statins (Moscow Statin Survey, MSS). Serdtse 2006; 5 (6) :324–8 (Сусеков А.В., Зубарева М.Ю., Деев А.Д. и др. Основ- ные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006;5(6):324–8).</mixed-citation><mixed-citation xml:lang="en">Susekov A., M. Zubarev, Deev AD etc. The main results of the Moscow study on statins (Moscow Statin Survey, MSS). Serdtse 2006; 5 (6) :324–8 (Сусеков А.В., Зубарева М.Ю., Деев А.Д. и др. Основ- ные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006;5(6):324–8).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middleincome, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231–43.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middleincome, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231–43.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lee HY, Cooke CE, Robertson TA. Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge. J Manag Care Pharm 2008;14(3):271–80.</mixed-citation><mixed-citation xml:lang="en">Lee HY, Cooke CE, Robertson TA. Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge. J Manag Care Pharm 2008;14(3):271–80.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ambardekar AV, Fonarow GC, Dai D, et al. Get With The Guidelines Steering Committee and Hospitals. Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). Am J Cardiol 2010;105(2):139–43.</mixed-citation><mixed-citation xml:lang="en">Ambardekar AV, Fonarow GC, Dai D, et al. Get With The Guidelines Steering Committee and Hospitals. Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). Am J Cardiol 2010;105(2):139–43.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med 2002;162:797–804.</mixed-citation><mixed-citation xml:lang="en">Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med 2002;162:797–804.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Drozdova LY, Lukina YV, et al. How to evaluate the possibility of practitioners of modern medical therapy in patients with chronic ischemic heart disease. Results of polls in Moscow and Voronezh. Rational Pharmacother Card 2010, 6 (2): 145–148. Russian (Марцевич С.Ю., Дроздова Л.Ю., Лукина Ю.В., и др. Как оценивают практические врачи возможности современной ме- дикаментозной терапии больных хронической ишемической болезнью сердца. Результаты опросов в Москве и Воронеже. РФК 2010; 6(2): 145–148).</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Drozdova LY, Lukina YV, et al. How to evaluate the possibility of practitioners of modern medical therapy in patients with chronic ischemic heart disease. Results of polls in Moscow and Voronezh. Rational Pharmacother Card 2010, 6 (2): 145–148. Russian (Марцевич С.Ю., Дроздова Л.Ю., Лукина Ю.В., и др. Как оценивают практические врачи возможности современной ме- дикаментозной терапии больных хронической ишемической болезнью сердца. Результаты опросов в Москве и Воронеже. РФК 2010; 6(2): 145–148).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Drozdova LY, Martsevich SY, Voronina VP. Simultaneous assessment of the prevalence and effectiveness of management of risk factors for cardiovascular disease among physicians and their knowledge of current clinical practice guidelines. The results of the project “Health and medical education”. Rational Pharmacother Card 2011, 7 (2) :137–144Russian (Дроздова Л.Ю., Марцевич С.Ю., Воронина В.П. Одновременная оценка распространенности и эффективности коррекции факторов риска сердечно-сосудистых заболеваний среди врачей и их знания современных клинических рекомендаций. Результаты проекта ≪Здоровье и образование врача≫. РФК 2011;7(2):137–144).</mixed-citation><mixed-citation xml:lang="en">Drozdova LY, Martsevich SY, Voronina VP. Simultaneous assessment of the prevalence and effectiveness of management of risk factors for cardiovascular disease among physicians and their knowledge of current clinical practice guidelines. The results of the project “Health and medical education”. Rational Pharmacother Card 2011, 7 (2) :137–144Russian (Дроздова Л.Ю., Марцевич С.Ю., Воронина В.П. Одновременная оценка распространенности и эффективности коррекции факторов риска сердечно-сосудистых заболеваний среди врачей и их знания современных клинических рекомендаций. Результаты проекта ≪Здоровье и образование врача≫. РФК 2011;7(2):137–144).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Eagle KA, Montoye CK, Riba AL, et al. Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction: The American College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005;46;1242–1248.</mixed-citation><mixed-citation xml:lang="en">Eagle KA, Montoye CK, Riba AL, et al. Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction: The American College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005;46;1242–1248.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">LaBresh KA, Fonarow GC, Smith SC Jr, et al. Get With The Guidelines Steering Committee. Improved treatment of hospitalized coronary artery disease patients with the get with the guidelines program. Crit Pathw Cardiol 2007;6:98–105.</mixed-citation><mixed-citation xml:lang="en">LaBresh KA, Fonarow GC, Smith SC Jr, et al. Get With The Guidelines Steering Committee. Improved treatment of hospitalized coronary artery disease patients with the get with the guidelines program. Crit Pathw Cardiol 2007;6:98–105.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Newby LK, LaPointe NM, Chen AY, et al. Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease. Circulation 2006;113:203–212.</mixed-citation><mixed-citation xml:lang="en">Newby LK, LaPointe NM, Chen AY, et al. Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease. Circulation 2006;113:203–212.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis WR, Ellrodt AG, Peterson E, et al. Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly: Findings From the Get With the Guidelines Quality- Improvement Program. Circ Cardiovasc Qual Outcomes 2009;2;633–641.</mixed-citation><mixed-citation xml:lang="en">Lewis WR, Ellrodt AG, Peterson E, et al. Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly: Findings From the Get With the Guidelines Quality- Improvement Program. Circ Cardiovasc Qual Outcomes 2009;2;633–641.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
